近年来，生物制造的热度居高不下，作为新兴的战略性领域，生物制造因其创新性和对传 统生产方式的颠覆性，被视为新的增长点，有助于推动产业结构优化和经济模式的转变。 由药融圈&Synbio深波联合发起，药融圈产业研究院精心编纂的 《2025中国合成生物制造产业发 展白皮书》 （以下简称《研究报告》），已于8月1日 在Synbio China 第三届中国合成生物学"科 学家+企业家+投资家"博览会正式发布！ 本白皮书介绍了生物制造的发展现状及趋势，分析了生物制造的产业链和重点应用方向， 并精选 出中国生物制造产业10大链主企业，整理了15家上市公司合成生物学布局方向以及20大热门品种 ，同时探讨了生物制造面临的挑战，最终提出了针对性的政策建议，供业内参考 。 领取方式： 关注本公众号，扫码添加下方微信获取 添加请备注：单位+职位+姓名 封面一览 Synthetic Biology 深波 1 251 息息与人脉精准链接平台 2025中国合成生物 制造产业发展白皮书 China's synthetic biomanufacturing industry Development White Paper 目录 | 前言 …… ...

每经AI快讯，嘉必优（SH 688089，收盘价：25.79元）10月9日晚间发布公告称，截至2025年9月30日， 公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约72万股，占公司总股本约 1.68亿股的比例为0.43%，最高成交价为28.58元/股，最低成交价为25.46元/股，累计成交总金额约为 1962万元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 王晓波） 截至发稿，嘉必优市值为43亿元。 2024年1至12月份，嘉必优的营业收入构成为：人类营养占比94.27%，动物营养占比2.96%，其他业务 占比2.4%，个人护理及化妆品占比0.38%。 ...

关于第二期以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2025 年 月 | 1 | 25 | 日 | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月内 | | | | | 预计回购金额 | 1,500 万元（含）-3,000 | | | 万元（含） | | 回购用途 | □减少注册资本 用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 715,458 | 股 | | | | 累计已回购股数占总股本比例 | 0.43% | | | | | 累计已回购金额 | 19,624,295.97 元 | | | | | 实际回购价格区间 | 25.46 元/股~28.58 元/股 | | | | 重要内容提示： 一、回购股份的基本情况 2025 年 1 月 24 日，公司召开 ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]

北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况的专项核查意见 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金 终止发行股份及支付现金 购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况 的专项核查意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于嘉必优生物技术（武汉）股份有限公司 终止发行股份及支付现金购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况的专项核查意见 购买资产并募集配套资金暨关联交易 相关主体自查期间内买卖股票情况 的专项核查意见 德恒 02F20240602-00007 号 致：嘉必优生物技术（武汉）股份有限公司 北京德恒律师事务所（以下简称"德恒"或"本所"）接受嘉必优生物技术 （武汉）股份有限公司（以下简称"嘉必优"或"上市公司"）之委托，担任嘉必 ...

国泰海通证券股份有限公司 关于嘉必优生物技术（武汉）股份有限公司终止本次交易 相关主体买卖股票情况的自查报告之专项核查意见 鉴于嘉必优生物技术（武汉）股份有限公司（以下简称"上市公司""嘉必 优"）拟通过发行股份及支付现金方式购买上海欧易生物医学科技有限公司 63.2134%股权并发行股份募集配套资金暨关联交易（以下简称"本次交易"）， 上市公司于 2025 年 8 月 29 日召开第四届董事会第八次会议、第四届监事会第 八次会议，审议通过了《关于终止发行股份及支付现金购买资产并募集配套资 金暨关联交易事项并撤回申请文件的议案》《关于公司与交易对方签署相关终止 协议的议案》，同意上市公司终止发行股份及支付现金购买资产并募集配套资金 暨关联交易事项并撤回申请文件，以及与交易对方签署相关终止协议。 根据《上市公司重大资产重组管理办法》《上海证券交易所上市公司自律监 管指引第 6 号——重大资产重组》等相关法律法规的要求，国泰海通证券股份 有限公司（以下简称"国泰海通""独立财务顾问"）作为本次交易的独立财务 顾问，对本次交易相关主体买卖股票的情况进行了核查，具体情况如下： 一、本次交易相关主体买卖股票情况自查期间 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-073 嘉必优生物技术（武汉）股份有限公司 关于终止发行股份及支付现金购买资产并募集配套资金暨关 联交易事项相关主体买卖股票情况自查报告的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"、"上市公司"或 "嘉必优"）拟通过发行股份及支付现金方式，购买王树伟、董栋、肖云平、王 修评、靳超、史贤俊、上海帆易生物科技合伙企业（有限合伙）、宁波梅山保税 港区睿欧投资管理合伙企业（有限合伙）、宁波梅山保税港区欧润企业管理合伙 企业（有限合伙）、上海国药二期股权投资基金合伙企业（有限合伙）、南通东证 瑞象创业投资中心（有限合伙）、苏州鼎石汇泽生物产业投资基金合伙企业（有 限合伙）、上海圣祁投资管理合伙企业（有限合伙）合计持有的上海欧易生物医 学科技有限公司 63.2134%股权并发行股份募集配套资金暨关联交易（以下简称 "本次交易"）。 公司于 2025 年 8 月 29 日召开第四届董事会第八次会议、第四届监事会第 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company has established a strong market position in the production of Arachidonic Acid (ARA) and Docosahexaenoic Acid (DHA), with significant growth potential driven by domestic and international demand [8][13]. - The company is expected to benefit from the expiration of patents held by competitors, allowing for increased market share and revenue growth [8][47]. - The financial forecasts indicate robust revenue and profit growth, with a projected revenue increase from 7.00 billion yuan in 2025 to 9.43 billion yuan in 2027, and net profit rising from 1.76 billion yuan to 2.55 billion yuan in the same period [1][8]. Summary by Sections 1. Company Overview - Founded in 2004, the company has pioneered the industrialization of ARA, DHA, and other products, with applications in human nutrition, animal nutrition, and personal care [8][13]. - The company has established long-term partnerships with global nutrition and dairy companies, exporting products to over 30 countries [8][13]. 2. Market Position and Growth - The company holds a market share of 13.5% globally and over 50% domestically in the ARA sector as of 2021, with expectations for further growth due to patent expirations of competitors [47]. - The domestic ARA market has shown a CAGR of 9.85% from 2015 to 2021, driven by rising disposable incomes and regulatory changes [46]. 3. Financial Performance - Revenue is projected to grow from 443.80 million yuan in 2023 to 942.93 million yuan by 2027, with a CAGR of 25.19% from 2023 to 2024 [1]. - Net profit is expected to increase from 91.37 million yuan in 2023 to 255.02 million yuan by 2027, reflecting a strong CAGR of 41.95% in 2024 [1]. 4. Product Segmentation - ARA is projected to account for approximately 70.2% of revenue in 2024, while DHA is expected to contribute 19.6% [15][26]. - The company is diversifying its product offerings, including SA and β-carotene, to enhance its market presence [15][13]. 5. Strategic Initiatives - The company is focusing on expanding its international market presence, particularly in light of the expiration of patents held by competitors, which will allow for competitive pricing and increased market penetration [8][47]. - The strategic direction emphasizes a dual focus on human nutrition and animal nutrition, with ongoing investments in product development and market expansion [8][13].

Group 1 - Dongwu Securities issued a report on September 18, giving a "Buy" rating to Jiabiyou (688089.SH) [1] - The rating is based on three main reasons: diversified layout, technological leadership, and increasing demand [1] - The company is focusing on both internal and external growth strategies [1] Group 2 - The report highlights a dual-driven approach that emphasizes technological advancement [1] - There are concerns regarding market competition and rising raw material costs [1]

Group 1 - The company, Jia Bi You Biotechnology (Wuhan) Co., Ltd., approved a share repurchase plan with a total fund of 15 million to 30 million yuan, with a maximum repurchase price of 25 yuan per share, valid for up to 12 months from the board's approval date [1] - On September 8, 2025, the company adjusted the maximum repurchase price from 24.80 yuan to 35 yuan per share due to changes in annual equity distribution and market conditions [1] - The company executed its first share repurchase on September 9, 2025, buying back 428,091 shares, which is 0.25% of the total share capital, with a total transaction amount of approximately 11.99 million yuan [1]